Apixaban to Prevent Decompensation of Early Liver Cirrhosis Trial

NCT07726693 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

1142

Enrollment

OTHER

Sponsor class

Conditions

Liver Cirrhosis

Interventions

DRUG: Apixaban 2.5 mg twice daily
DRUG: Placebo

Sponsor

University College, London

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]